Remnant lipoproteins and impact of PCSK9 inhibition
Genome-wide polygenic risk scores: Insights from ODYSSEY OUTCOMES
Genetic risk scores: How much do they add?
What’s new in very high-risk patients?
Do the new ESC/EAS guidelines change your clinical practice? Acute coronary syndromes
ODYSSEY OUTCOMES and stroke events
Treat ischaemic stroke to target
Endothelial LDL transcytosis in atherosclerosis
Emerging lipid science: ApoE and chronic disease
ODYSSEY OUTCOMES: Update
New data from FOURIER and design of the VESALIUS-CV Trial
PCSK9 Genetics: New Insights
Jan Boren Hepatic lipid metabolism: Storage vs secretion
Using naturally randomized genetic evidence to estimate the clinical benefit of lowering triglyceride-rich lipoproteins
Erik Stroes New approaches to treatment of moderate hypertriglyceridemia and new therapeutic combinations
Frederick J. Raal Inclisiran: The Phase 3 trial
Peter Sever FOURIER trial: Update on subgroup analyses
Andreas M Zeiher ODYSSEY OUTCOMES: Update
Henry Ginsberg The new AHA/ACC Treatment Guidelines: Critical appraisal
Børge Nordestgaard Is it time to upgrade Lp(a) to a therapeutic target in Guidelines?